Abstract
Diffuse large B cell lymphoma is a collection of different biologic entities with a common appearance but different clinical behaviors. The MYC oncogene is mutated in a subset of diffuse large B cell lymphoma and is also mutated in related entities such as Burkitt lymphoma. Recently, an antibody to the c-Myc oncoprotein has become available for immunohistochemistry, raising the possibility of a rapid, reproducible and inexpensive measure of MYC abnormality. Initial retrospective studies of these lymphomas suggest that the c-Myc status is clinically important for diagnosis and prognosis, particularly when used in conjunction with BCL2 immunohistochemistry. It is possible that therapy will be modified based in part on c-Myc status, once the appropriate prospective studies have been performed.
Original language | English (US) |
---|---|
Pages (from-to) | 234-238 |
Number of pages | 5 |
Journal | Pathology Case Reviews |
Volume | 19 |
Issue number | 5 |
DOIs | |
State | Published - Dec 10 2014 |
Keywords
- BCL2
- DLBCL
- Diffuse large B cell lymphoma
- Immunohistochemistry
- MYC
ASJC Scopus subject areas
- Pathology and Forensic Medicine